Company intelligence / Profile preview

Boyuan Capital

Shanghai, Shanghai, China

Ownership: Private
Employees: ~30
Development stage: Other

Overview

Boyuan Capital, also known as BioTrack Capital, is a leading healthcare-focused venture capital firm based in China. Founded in 2017 by experienced investors including Kevin Chen, the firm specializes in early and growth-stage investments across the life sciences, medical devices, and digital health sectors. Boyuan Capital aims to support innovative companies that address significant unmet medical needs in China and globally. Their portfolio includes prominent biotech and medtech companies such as Cansino Biologics, New Horizon Health, and RemeGen. The firm leverages its deep industry expertise and extensive network to provide strategic value to its portfolio companies.

Industry: Investors

Beyond the preview

Go deeper on Boyuan Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Boyuan Capital.

Explore the full profile